Androgenetic Alopecia
Conditions
Brief summary
The current study aims to show efficacy of twice daily application of 5% Minoxidil Topical Foam (MTF) formulation compared to placebo in the temple region of male patients with androgenetic alopecia after 24 weeks as well as to gain long-term data on the efficacy and safety of 5% MTF in male subjects with AGA in temple and vertex region, over a period of 2 years. Objective and subjective efficacy measures will be compared to baseline. Moreover, all patients will get the equal treatment and measurements in the vertex region to enable comparison of the efficacy of 5% Minoxidil Topical Foam in the temples not only to baseline but also to vertex region. Additionally safety assessments will be performed throughout the whole study.
Interventions
DRUGMinoxidil
1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
DRUGvehicle of 5% Minoxidil topical foam
1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
Sponsors
Johnson & Johnson
Natalie GARCIA BARTELS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male, age 18 to 70 year old, in general good health * Exhibits male AGA based on a discernable hair loss in temple and vertex region rating Hamilton-Norwood Scale III vertex to VI (See Appendix 1) * Subjects who give their consent to the study after thorough explanation and who personally signed and dated the informed consent document indicating that the subject, has been informed of all pertinent aspects of the trial * Willing to maintain the same hairstyle, hair length and hair color throughout the study * Subjects who are willing and able to comply with scheduled visits, treatment plan, mini-tattoo and other trial procedures * Accepting the Information form plus accepting and signing the Informed Consent form
Exclusion criteria
* Known to be hypersensitive to minoxidil, hair dye (p-phenylenediamine), tattoo ink, fragrances, hair gel or any vehicle components * Current or 4 weeks dated back use of medical shampoos or solutions which include Ketoconazole or the like (e. g. Terzolin®) in the target region interfering with the CTM or examination method * Current or 3 months dated back use of topical treatment in the target regions taken for more then 2 consecutive weeks interfering with the CTM (topical corticosteroids, aminexil, minoxidil, estrogens) * Current or 3 months dated back use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the CTM or examination method (beta blocker, cimetidine, diazoxide, isotretionin, corticosteroids, vitamin A intake above 10000 IU per day) * Current or 12 months dated back use of Finasteride (Propecia®, FinaHair®, etc.), Dutasteride or a similar product * Within past 12 months undergoing chemotherapy or receiving cytotoxic agents as well as radiation and/or laser/surgical therapy of the scalp * Current or prior enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation * Presence of hair transplants, hair weaves or non-breathable wigs and hair bonding * Current or 2 months dated back severe diet or presenting a history of eating disorder * Any dermatological disorders of the scalp in the target region with the possibility of interfering with the CTM or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy * Untreated persisting hypertension * Active hair loss or history within the past 3 months including diffuse telogen effluvium, alopecia areata, scarring alopecia * Other severe, acute or chronic medical condition that may lead to hair loss or interfere with the interpretation of trial results (e. g. untreated hypothyroidism) * Individuals who are institutionalized by court or regulatory order
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of target area non-vellus hair count in the temple region (t-TAHC) [n/cm²] compared to baseline after 24 weeks | Baseline, week 8, week 16, week 24, week 52, week 76, week 104 |
Secondary
| Measure | Time frame |
|---|---|
| Assessing the investigational products safety by means of clinical examination (local intolerance, AE, SAE) | every visit from baseline to week 104 |
| Change of cumulative hair width in non-vellus hair in temple and vertex region (t-TAHW; v-TAHW) [mm/cm²] compared to baseline after 24, 52, 76 and 104 weeks | Baseline, week 8, week 16, week 24, week 52, week 76, week 104 |
| Change of t-TAHC, v-TAHC, t-TAHW and v-TAHW comparing 5% MTF and Placebo Topical Foam (plaTF) groups | Baseline, week 8, week 16, week 24, week 52, week 76, week 104 |
| Global expert panel and subjects' rating change in scalp coverage: week 24 compared to baseline, week 104 compared to baseline and week 104 compared to week 24 via assessment of global temple and vertex photographs | Baseline, week 8, week 16, week 24, week 52, week 76, week 104 |
Countries
Germany
Outcome results
None listed